SCHEMBL19384151

SCHEMBL19384151

CN(CCOc1ccccc1CC#N)C(=O)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 3/20 0.46
DRD2 P14416 2/20 0.45
DRD1 P21728 2/20 0.45
DRD4 P21917 1/20 0.45
DRD5 P21918 1/20 0.45
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
DRD3 P35462 1/20 0.41
ALDH1A1 P00352 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
F13A1 P00488 1/20 0.38
TGM2 P21980 1/20 0.38
TGM1 P22735 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19384152 0.84 KDM4E (0.49) HRH1DRD2DRD1DRD4DRD5
SCHEMBL524847 0.84 ALDH1A1 (0.44) HRH1KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL19384156 0.81 CTSL (0.38) HRH1KDM4EALDH1A1SMN1; SMN2CTSL
SCHEMBL29777971 0.78 ALDH1A1 (0.43) HRH1KDM4ELMNAALDH1A1
SCHEMBL10102483 0.77 ALDH1A1 (0.40) HRH1DRD2DRD1DRD4DRD5
SCHEMBL19384157 0.77 HTR1D (0.58) HRH1DRD2DRD1DRD4DRD5
SCHEMBL10102481 0.77 HRH1 (0.40) HRH1DRD2DRD1DRD4DRD5
SCHEMBL524534 0.76 HDAC1 (0.39) HRH1DRD2DRD1DRD4DRD5
SCHEMBL7367495 0.75 ALDH1A1 (0.58) LMNAALDH1A1KMT2AF13A1TGM2
SCHEMBL19384145 0.75 HDAC1 (0.38) HRH1DRD2DRD1DRD4DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190100498-A1 CRYSTALLINE FORM ASTRAZENECA AB (SE) 2019-04-04 US disclosed
US-20190100498-A1 CRYSTALLINE FORM ASTRAZENECA AB (SE) 2019-04-04 US disclosed
EP-3433237-A1 CRYSTALLINE FORM Astrazeneca AB (SE) 2019-01-30 EP disclosed
WO-2017162304-A1 CRYSTALLINE FORM ASTRAZENECA AB (SE) 2017-09-28 WO disclosed
WO-2017162304-A1 CRYSTALLINE FORM ASTRAZENECA AB (SE) 2017-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190100498-A1 CRYSTALLINE FORM GYS2, PYGL, SFPQ HRH1 4086/4885DRD2 4835/4885DRD1 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.